Page 103 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Epidemiology of Primary Systemic Vasculitis 79

[14] Haugeberg, G., Paulsen, P. Q., Bie, R. B. Temporal arteritis in Vest Agder County in
southern Norway: incidence and clinical findings. J. Rheumatol. 2000; 27:2624-2627.

[15] Gonzalez-Gay, M. A., Barros, S., Lopez-Diaz, M. J., Garcia-Porrua, C., et al. Giant cell
arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine
2005; 84:269-276.

[16] Gonzalez-Gay, M. A., Miranda-Filloy, J. A., Lopez-Diaz, M. J., et al. Giant cell arteritis
in northwestern Spain. A 25-year epidemiological study. Medicine 2007; 86:61-68.

[17] Mohammad, A. J., Nilsson, J. A., Jacobsson, L. T., et al. Incidence and mortality rates
of biopsy-proven giant cell arteritis in southern Sweden. Ann. Rheum. Dis. 2014 Jan. 17
[Epub. ahead of print].

[18] Smeeth, L., Cook, C., Hall, A. J. Incidence of diagnosed polymyalgia rheumatica and
temporal arteritis in the United Kingdom, 1990-2001. Ann. Rheum. Dis. 2006; 65:1093-
1098.

[19] Salvarani, C., Crowson, C. S., O?Fallon, M., et al. Reappraisal of the epidemiology of
giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis
Rheum. 2004; 51:264-268.

[20] De Souza, A. W., Okamoto, K. Y. K., Abrantes, F., et al. Giant cell arteritis: a
multicenter observational study in Brazil. Clinics (Sao Paulo) 2013; 68:317-322.

[21] Chaudhry, I. A., Shamsi, F. A., Elzaridi, E., et al. Epidemiology of giant-cell arteritis in
an Arab population: a 22-year study. Br. J. Ophthalmol. 2007; 91:715-718.

[22] Alba, M. A., Mena-Madrazo, J. A., Reyes, E., et al. Giant cell arteritis in Mexican
patients. J. Clin. Rheumatol. 2012; 18:1-7.

[23] Kobayshi, S., Yano, T., Matusmoto, Y., et al. Clinical and epidemiological analysis of
giant cell (Temporal) arteritis from a nationwide survey in 1998: The first government-
supported nationwide survey. Arthritis Rheum. 2003; 49:594-598.

[24] Lane, S. E., Watts, R., Scott, D. G. I. Epidemiology of systemic vasculitis. Curr.
Rheumatol. Rep. 2005; 7:270-275.

[25] Kemp, A., Marner, K., Nissen, S. H., et al. HLA antigens in cases of giant cell arteritis.
Acta Ophthalmol. (Copenh.) 1980; 58:1000-1004.

[26] Armstrong, R. D., Behn, A., Myles, A., et al. Histocompatibility antigens in
polymyalgia rheumatica and giant cell arteritis. J. Rheumatol. 1983; 10:659-661.

[27] Dababneh, A., Gonzalez-Gay, M. A., Garcia-Porrua, C., et al. Giant cell arteritis and
polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II
association. J. Rheumatol. 1998; 25:2140-2145.

[28] Jacobsen, S., Baslund, B., Madsen, H. O., et al. Mannose-binding lectin variant alleles
and HLA-DR4 alleles are associated with giant cell arteritis. J. Rheumatol. 2002; 29:
2148-2153.

[29] Bignon and colleagues (Bignon, J. D., Ferec, C., Barrier, J., et al.) HLA class II genes
polymorphism in DR4 giant cell arteritis patients. Tissue Antigens 1988; 32:254-258.

[30] Bignon, J. D., Barrier, J., Soulillou, J. P., et al. HLA DR4 and giant cell arteritis. Tissue
Antigens 1984; 24:60-62.

[31] Richardson, J. E., Gladman, D. D., Fam, A., et al. HLA-DR4 in giant cell arteritis:
association with polymyalgia rheumatica syndrome. Arthritis Rheum. 1987; 30:1293-
1297.

[32] Barrier, J., Bignon, J. D., Soulillou, J. P., et al. Increased prevalence of HLA-DR4 in
giant-cell arteritis. N. Engl. J. Med. 1981; 305:104-105.

Complimentary Contributor Copy